Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy
暂无分享,去创建一个
M. Tormo | C. McMahon | T. Cluzeau | S. Gore | A. Fathi | M. Sekeres | V. Bhatt | A. Brunner | U. Germing | J. Neukirchen | R. Itzykson | G. Roboz | J. Bewersdorf | A. Zeidan | S. Luger | E. Raffoux | I. Khan | E. Ritchie | R. Rodríguez-Veiga | P. Montesinos | B. Boluda | D. Martínez-Cuadrón | E. Lengliné | H. Konig | R. Shallis | Wei Wei | N. Podoltsev | E. Rabinovich | M. Stahl | F. Rabian | J. Umakanthan | Adam M. Miller | B. Yoo | I. Cano | Sudipto Mukhereje | E. Cruz | Evelyn Gloria Acuna Cruz
[1] M. Tormo,et al. Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multi-center, international study , 2020, Leukemia.
[2] Xiaomei Ma,et al. Temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States: A population‐level analysis , 2019, Cancer.
[3] J. Bewersdorf,et al. The golden age for patients in their golden years: The progressive upheaval of age and the treatment of newly-diagnosed acute myeloid leukemia. , 2019, Blood reviews.
[4] Xiaomei Ma,et al. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. , 2019, Blood reviews.
[5] J. Armitage,et al. Utilization of initial chemotherapy for newly diagnosed acute myeloid leukemia in the United States. , 2018, Blood advances.
[6] Sinyoung Kim,et al. The effect of therapeutic leukapheresis on early complications and outcomes in patients with acute leukemia and hyperleukocytosis: a propensity score‐matched study , 2018, Transfusion.
[7] J. Ensor,et al. Leukapheresis reduces 4-week mortality in acute myeloid leukemia patients with hyperleukocytosis – a retrospective study from a tertiary center , 2017, Leukemia & lymphoma.
[8] Bob Löwenberg,et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.
[9] G. Ehninger,et al. How I treat hyperleukocytosis in acute myeloid leukemia. , 2015, Blood.
[10] P. Mintz,et al. Hyperleukocytosis, leukostasis and leukapheresis: practice management. , 2012, Blood reviews.
[11] S. Shelat. Practical considerations for planning a therapeutic apheresis procedure. , 2010, The American journal of medicine.
[12] Yu Shen,et al. Leukapheresis Reduces Early Mortality in Patients with Acute Myeloid Leukemia with High White Cell Counts But Does Not Improve Long Term Survival , 2001, Leukemia & lymphoma.
[13] X. Thomas,et al. Impact of pre-induction therapy leukapheresis on treatment outcome in adult acute myelogenous leukemia presenting with hyperleukocytosis , 2000, Annals of Hematology.
[14] P. Porcu,et al. Hyperleukocytic Leukemias and Leukostasis: A Review of Pathophysiology, Clinical Presentation and Management , 2000, Leukemia & lymphoma.
[15] N. Heerema,et al. Therapeutic leukapheresis in hyperleucocytic leukaemias: lack of correlation between degree of cytoreduction and early mortality rate , 1997, British journal of haematology.
[16] J. Dutcher,et al. Hyperleukocytosis in adult acute nonlymphocytic leukemia: impact on remission rate and duration, and survival. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.